Business Wire

The Listing of Money Trade Coin on Cryptocurrency Exchange and the Rising Promise of a New Era in Dubai

Del

MONEY TRADE COIN, the new age cryptocurrency, dazzled its investors’ expectations by listing on NovaExchange. Immediate trading began post the launch by Money Trade Coin’s founder and CEO, Mr. Amit Lakhanpal and H.E. Sheikh Saqer Al Nahyan. The listing event held on September 17 at Burj Al Arab was witnessed by a list of 40 VIP businessmen including H.E. Sheikh Jumaa Al Maktoum, Mr. Faisal Almaazmi, his principal advisor and director of Greenland Capital Properties, Mr. Charles Said Kiwan founder of MVP Tech and Mr. Khaled Abdulla, Head of Communications MENA at Barclays PLC.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170921006013/en/

Amit Lakhanpal greets H.E. Sheikh Saqer Al Nahyan (Photo: AETOS Wire)

Amit Lakhanpal greets H.E. Sheikh Saqer Al Nahyan (Photo: AETOS Wire)

Money Trade Coin, the propagator of the “Cryptocurrency correct knowledge” launched a full-fledged product array: Cryptocurrency E-Academy and E-Portal. The trading platform offers the possibility to interexchange the different cryptocurrency coins such as BitCoin, Ethereum, Ripple, Moreno, and shall be trading all the 1,088 listed coins soon. It plans to go live on more than four exchanges: C6, Coinex, Poloniex and their own private exchange as its listing became a bold statement that investors demand has increasingly swept from traditional practices to digital currency as a secure alternative to safeguard wealth, eliminate costs, increase efficiency and flexibility, and save time while transacting.

Unique in its features “MONEY TRADE COIN” is a registered certified entity with a recognized identity, Mr. Amit Lakhanpal, a well-known businessman heading the Flintstone Group India and its IP is jointly owned by Bitcoin Global FZE, UAE and Money Trade Coin UK Ltd, licensed in: United Kingdom, Estonia, soon in Switzerland and India. Flintstone Technologies Private Limited, the Indian exchange platform, shall be launched on 19 October, 2017.

Acquiring “MONEY TRADE COIN” is limited to the transfer of existing Bitcoin, online gateway (credit/debit cards and PayPal), and traditional banking methods shall be established soon. The physical and digital card will be available in select countries. The value can be redeemed with various options such as online shopping, airline tickets among others. The currency will not only be limited to entertainment or ticketing but also to pay government taxes, utility bills and fines across GCC region, Asian and European countries as well.

Amit, published a book on Inter Cryptocurrency trading for Beginners and established a solid corporate sustainability program where 5% of the trading profits shall be given to the Charity Organizations of the UAE Government and 15% customized on welfare trusts sponsored run by the company.

Money Trade Coin eyed the Emirate of Dubai for its new expansion as the “Next Big Hit”, incorporation started supported by “Khalifa Bin Huwaidan Al Ketbi Advocates and Legal consultants” and Advocate Hashim Malik since Dubai, adopted the “Dubai Blockchain Strategy” for 2020 launched by H.H. Sheikh Hamdan Al Maktoum, under the directive of H.H. Sheikh Mohammed Bin Rashed Al Maktoum, the ruler of Dubai.

Money Trade Coin, ultra-secure wallet through multi-level verifications, is the world’s first fully secured Cryptocurrency, implementing the highest standards of compliance: KYC and AML keeping the records of all transactions for more than ten years. MONEY TRADE Initial Coin Offering (ICO) was held in 4 phases, 14 Million MT Coins were offered at each phase, the minimum subscription was capped at 1 MT Coin. As per the experts, Money Trade Coin is forecasted to exceed the value of USD 500 per coin this year across cryptocurrency exchanges.

*Source: AETOS Wire

Contact information

for Money Trade Coin
Kalpana Desai, +919833226461
kalpana@falcongroup.co.in

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Andersen Global Expands Presence in Germany with Addition of Thierhoff Müller & Partner13.12.2017 08:01Pressemelding

Andersen Global is proud to announce an expanded presence in Germany as Thierhoff Müller & Partner, a tax and legal firm with offices in Leipzig and Frankfurt, combines its practice with Andersen Tax & Legal in Germany. Through its German member firms, Andersen Tax & Legal and Alegis Steuerberatungsgesellschaft mbH, Andersen Global now has more than 65 professionals focused on providing tax and legal services and business advice across five locations in Germany, including Cologne, Dusseldorf, and Merzig. “Thierhoff Müller is highly regarded in complex restructuring matters. Together with our existing legal and tax practice, we will be able to increase our service offerings for our clients,” said Stefan Kraus, Managing Partner of Andersen Tax & Legal in Germany. “We are dedicated to providing outstanding service and are adding additional competencies in tax and legal such as corporate r

Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs13.12.2017 08:00Pressemelding

Aprecia Pharmaceuticals, LLC (“Aprecia”), The 3DP Pharmaceutical Company, and Cycle Pharmaceuticals, Ltd. (“Cycle”) today announced they have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (“3DP”) technology. The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia’s proprietary 3DP ZipDose® Technology platform. ZipDose® is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food and Drug Administration. Antonio Benedetti, CEO of Cycle commented: “Many rare disease patients do not have a treatment option at all. For those rare diseases where there is an approved pharmaceutical treatment, patients continue to be burdened by sub-optimal drug formulations. Aprecia’s

Group Vivendi Africa Deploys Netcracker OSS to Enhance Service Management as it Expands Across the Continent12.12.2017 16:07Pressemelding

Netcracker Technology announced today that its OSS suite was selected and deployed to support the long-term growth strategy of Group Vivendi Africa (GVA). GVA is a newly formed affiliate of the French-based multinational conglomerate Vivendi with the goal to deploy and operate a fiber network across Africa. Netcracker's OSS will be used as a consolidated solution to identify service availability across GVA's operating countries and then fulfill and provision those services to customers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005937/en/ Netcracker's highly productized, out-of-the-box applications enabled the OSS suite to be deployed in seven months, meeting GVA's demand to leverage an integrated service fulfillment and inventory solution that could satisfy its long-term growth expectations, as well as s

Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23Pressemelding

Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s

Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00Pressemelding

Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid

Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33Pressemelding

Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom